Role of Interleukin-6 and Procalcitonin as Novel Inflammatory Biomarkers in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta

FARAH AFZAL

Status: Completed

Conditions: Covid19 Positive Patients

Treatments: Diagnostic Test: Interlukein 6 and procalcitonin serum levels

Study type: Interventional

Funder types: Other

Identifiers

NCT04945811

CMHQ3

Details and patient eligibility

About

Serum Interleukin-6 and Procalcitonin of 100 consenting COVID 19 positive patients from April 2020 - May 2021 were assessed at Pathology department CMH Quetta and the results were correlated with severity of lung involvement on HRCT Chest

Full description

Objective: To explore the relation between Interleukin-6 and Procalcitonin with COVID severity on HRCT Chest Study Design: Randomized Control Trial (Clinical Trials. gov Identifier: NCT04798391) Place and duration of study: Pathology, Radiology & ENT Department CMH Quetta from April 2020 - May 2021 Methodology: Serum Interleukin-6 and Procalcitonin of 100 consenting COVID 19 positive patients from April 2020 - May 2021 were assessed at Pathology department CMH Quetta and the results were correlated with severity of lung involvement on HRCT Chest Results: Serum Interlukin-6 levels were raised in 97 (97%) patients with mean levels of 20.43 + 19.66 (pg/ml). Serum procalcitonin levels were raised in 95 (95%) patients with mean levels of 0.4331 + 0.24 (ng/ml). A P value of <0.001 was calculated on Independent Sample T-test for both serum interlukin-6 and serum procalcitonin as correlated with severity of lung involvement on HRCT Chest.

Conclusion: Interlukin-6 and procalcitonin are excellent biomarkers for diagnosis and predicting severity of COVID19 pneumonia.

Keywords: Covid19 pneumonia, Interlukin-6, procalcitonin.

Enrollment: 100 patients

Sex: All

Ages: 38 to 71 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• positive PCR of COVID 19

Exclusion criteria

• NEGATIVE PCR of COVID 19

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Interlukein 6 and procalcitonin

Experimental group

Description:

Interlukein 6 and procalcitonin levels in COVID 19 patients

Treatment:

Diagnostic Test: Interlukein 6 and procalcitonin serum levels